UCB Ventures
UCB Ventures is an evergreen strategic corporate venture fund established in 2017, focused on creating value from novel insights and technologies to transform the lives of patients with severe diseases. The firm invests in early-stage companies in the US and Europe, particularly those developing novel therapeutic modalities and platforms that address novel biology. UCB Ventures is committed to long-term investments and works closely with entrepreneurs to maximize the potential of its portfolio companies.
UCB Ventures
Portfolio
Developing conditionally activated siRNA technology for central nervous system diseases.
#Biotechnology
Developing transformational, non-viral, genetic medicines to treat and potentially cure serious and life-threatening diseases.
#Biotechnology
Exploiting protein splicing to develop the next generation of gene therapies.
#Biotechnology
Developing an in vivo engineering platform to produce cancer-fighting cells inside the patient’s body.
#Biotechnology
Focused on the development of breakthrough treatments for neurological disorders.
#Biotechnology
Developing advanced stem cell-based therapeutics to treat hearing loss.
#Biotechnology
An VHH antiviral platform company focused on rapid control with a lead compound for COVID-19.
#Biotechnology
Developing a nanovesicle platform designed to deliver genetic therapeutic payloads to the specific site of action with unparalleled precision.
#Biotechnology
Developing a unique RNA therapeutics platform that enables universal allele selectivity in treating genetic diseases.
#Biotechnology
Developing a unique approach to gene editing using programmable recombinases to address genetic disease.
#Biotechnology
Key People
Head of UCB Ventures
UCB Ventures Partner
Venture Associate
UCB Ventures Analyst
Team Coordinator